Regulatory Consideration on Preparation and Clinical Use of COVID-19 Convalescent Plasma

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), spreading from Wuhan to worldwide has been emerged since December 2019. Although scientists and researchers have been racing to develop specific therapeutic agents or vaccines against SARS-CoV-2 since the identification of the agent, either a drug or a vaccine has not been approved to treat or to prevent COVID-19 up to date. On the base of historical experiences, Convalescent Plasma (CP), a passive antibody therapy, has been evaluated as a hopeful and potential therapeutic option since the beginning of the COVID-19 outbreak.

Source: Transfusion and Apheresis Science - June 3, 2020 Category: Hematology Authors: Y ılmaz Soner, Ertuğrul Örüç Nigar, Azap Alpay, Özcebe Osman, Çetin Türker, Yenicesu İdil, Öztürk Abdullah, Gündüz Mehmet, Tekin Ahmet Source Type: research